Follicum announced on July 31, 2018 that it had received a so-called Notice of Allowance from the US Patent and Trademark Office (“USPTO”) regarding the patent application “Novel Compositions and Uses Thereof”. Follicum today announces that the patent has now formally been granted by the USPTO. The patent number is US 10,137,169 and the patent is valid until 2032.
In this patent family, Follicum already has a granted US patent specifically covering FOL-005. Follicum has subsequently submitted a follow-up, so called Continuing Patent Application, which extends and broadens the protection of FOL-005. Follicum has now received a formal grant for this follow up application. The patent provides protection in the United States through until the year 2032. The USPTO will publish the granted patent on November 27, 2018.
CEO Jan Alenfall comments:
– The United States is one of the largest markets for Follicum, and hence this patent is of major importance to us. We are continuously working to strategically expand our patent portfolio in our key markets.
FOL-005 is a modified short version of the endogenous protein, osteopontin. In two completed clinical studies, FOL-005 proved to be an effective and safe treatment. Already after three months of treatment, a clear effect on hair growth could be detected. The patients have been injected three times a week in these studies. As the next step in the development, the company will plan to start a clinical effect study with a topical formulation of FOL-005 where dose, dosage frequency and treatment length will be optimized. In parallel, the company will focus on finding a suitable development partner for FOL-005.
For further information, please contact:
Jan Alenfall – CEO, Follicum AB
Telephone: +46 46 19 21 97
This information is information that Follicum is obliged to make public according to the EU Market Abuse Regulation. The information was provided through the agency of the contact persons above, for publication on the 21 November 2018.
About Follicum AB
Follicum is a biotech company focused on the discovery and development of peptide-based drugs. The primary focus is in hair growth stimulation, where Follicum has obtained very promising results with FOL-005 in a recently completed clinical trial. In diabetes, Follicums research has resulted in a new peptide class which significantly increases the release of insulin in pre-clinical models. The company was founded in 2011, and is based in Lund, Sweden. Follicum is listed on the Swedish small cap exchange Spotlight since 2014. www.follicum.com.